BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 27926483)

  • 1. The metastasis suppressor CD82/KAI1 inhibits fibronectin adhesion-induced epithelial-to-mesenchymal transition in prostate cancer cells by repressing the associated integrin signaling.
    Lee J; Byun HJ; Lee MS; Jin YJ; Jeoung D; Kim YM; Lee H
    Oncotarget; 2017 Jan; 8(1):1641-1654. PubMed ID: 27926483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastasis suppressor KAI1/CD82 attenuates the matrix adhesion of human prostate cancer cells by suppressing fibronectin expression and β1 integrin activation.
    Lee HA; Park I; Byun HJ; Jeoung D; Kim YM; Lee H
    Cell Physiol Biochem; 2011; 27(5):575-86. PubMed ID: 21691075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The metastasis suppressor CD82/KAI1 represses the TGF-β
    Lee MS; Lee J; Kim YM; Lee H
    Prostate; 2019 Sep; 79(12):1400-1411. PubMed ID: 31212375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases.
    Sridhar SC; Miranti CK
    Oncogene; 2006 Apr; 25(16):2367-78. PubMed ID: 16331263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Requirement of the p130CAS-Crk coupling for metastasis suppressor KAI1/CD82-mediated inhibition of cell migration.
    Zhang XA; He B; Zhou B; Liu L
    J Biol Chem; 2003 Jul; 278(29):27319-28. PubMed ID: 12738793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transmembrane interactions are needed for KAI1/CD82-mediated suppression of cancer invasion and metastasis.
    Bari R; Zhang YH; Zhang F; Wang NX; Stipp CS; Zheng JJ; Zhang XA
    Am J Pathol; 2009 Feb; 174(2):647-60. PubMed ID: 19116362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tetraspanin CD82 represses Sp1-mediated Snail expression and the resultant E-cadherin expression interrupts nuclear signaling of β-catenin by increasing its membrane localization.
    Lee MS; Byun HJ; Lee J; Jeoung DI; Kim YM; Lee H
    Cell Signal; 2018 Dec; 52():83-94. PubMed ID: 30189244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD151-α3β1 integrin complexes suppress ovarian tumor growth by repressing slug-mediated EMT and canonical Wnt signaling.
    Baldwin LA; Hoff JT; Lefringhouse J; Zhang M; Jia C; Liu Z; Erfani S; Jin H; Xu M; She QB; van Nagell JR; Wang C; Chen L; Plattner R; Kaetzel DM; Luo J; Lu M; West D; Liu C; Ueland FR; Drapkin R; Zhou BP; Yang XH
    Oncotarget; 2014 Dec; 5(23):12203-17. PubMed ID: 25356755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of KAI1/CD82 on the beta1 integrin maturation in highly migratory carcinoma cells.
    Jee BK; Lee JY; Lim Y; Lee KH; Jo YH
    Biochem Biophys Res Commun; 2007 Aug; 359(3):703-8. PubMed ID: 17560548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The peptide mimicking small extracellular loop domain of CD82 inhibits tumor cell migration, adhesion and induces apoptosis by inhibiting integrin mediated signaling.
    Luan M; He X; Huang X; Zhang Q; Ma K
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2206-2211. PubMed ID: 29953857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastasis-suppressor KAI1/CD82 induces homotypic aggregation of human prostate cancer cells through Src-dependent pathway.
    Jee B; Jin K; Hahn JH; Song HG; Lee H
    Exp Mol Med; 2003 Feb; 35(1):30-7. PubMed ID: 12642901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of urokinase receptor proteolytic function by the tetraspanin CD82.
    Bass R; Werner F; Odintsova E; Sugiura T; Berditchevski F; Ellis V
    J Biol Chem; 2005 Apr; 280(15):14811-8. PubMed ID: 15677461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MGAT3-mediated glycosylation of tetraspanin CD82 at asparagine 157 suppresses ovarian cancer metastasis by inhibiting the integrin signaling pathway.
    Li J; Xu J; Li L; Ianni A; Kumari P; Liu S; Sun P; Braun T; Tan X; Xiang R; Yue S
    Theranostics; 2020; 10(14):6467-6482. PubMed ID: 32483464
    [No Abstract]   [Full Text] [Related]  

  • 14. EWI2/PGRL associates with the metastasis suppressor KAI1/CD82 and inhibits the migration of prostate cancer cells.
    Zhang XA; Lane WS; Charrin S; Rubinstein E; Liu L
    Cancer Res; 2003 May; 63(10):2665-74. PubMed ID: 12750295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KAI1/CD82, a tumor metastasis suppressor.
    Liu WM; Zhang XA
    Cancer Lett; 2006 Aug; 240(2):183-94. PubMed ID: 16260083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The palmitoylation of metastasis suppressor KAI1/CD82 is important for its motility- and invasiveness-inhibitory activity.
    Zhou B; Liu L; Reddivari M; Zhang XA
    Cancer Res; 2004 Oct; 64(20):7455-63. PubMed ID: 15492270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetraspanin CD82 inhibits protrusion and retraction in cell movement by attenuating the plasma membrane-dependent actin organization.
    Liu WM; Zhang F; Moshiach S; Zhou B; Huang C; Srinivasan K; Khurana S; Zheng Y; Lahti JM; Zhang XA
    PLoS One; 2012; 7(12):e51797. PubMed ID: 23251627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alteration of integrin-dependent adhesion and signaling in EMT-like MDCK cells established through overexpression of calreticulin.
    Ihara Y; Inai Y; Ikezaki M
    J Cell Biochem; 2011 Sep; 112(9):2518-28. PubMed ID: 21557298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CX3CL1 increases invasiveness and metastasis by promoting epithelial-to-mesenchymal transition through the TACE/TGF-α/EGFR pathway in hypoxic androgen-independent prostate cancer cells.
    Tang J; Xiao L; Cui R; Li D; Zheng X; Zhu L; Sun H; Pan Y; Du Y; Yu X
    Oncol Rep; 2016 Feb; 35(2):1153-62. PubMed ID: 26718770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.